ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Epinephrine (adrenaline) (systemic): Drug information

Epinephrine (adrenaline) (systemic): Drug information
(For additional information see "Epinephrine (adrenaline) (systemic): Patient drug information" and see "Epinephrine (adrenaline) (systemic): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Adrenalin;
  • Adyphren Amp II [DSC];
  • Adyphren Amp [DSC];
  • Adyphren II [DSC];
  • Adyphren [DSC];
  • Auvi-Q;
  • Epinephrine Professional;
  • EPINEPHrinesnap;
  • EpinephrineSnap-EMS;
  • Epinephrinesnap-v;
  • EpiPen 2-Pak;
  • EpiPen Jr 2-Pak;
  • EPIsnap;
  • Symjepi [DSC]
Brand Names: Canada
  • Adrenalin;
  • Allerject;
  • Anapen;
  • Anapen Junior;
  • Emerade;
  • EpiPen;
  • EpiPen Jr
Pharmacologic Category
  • Alpha-/Beta- Agonist
Dosing: Adult

Dosage guidance:

Safety: Epinephrine dosage form concentrations are no longer labeled as ratio expressions (eg, 1:1,000); however, a ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (Ref).

Anaphylaxis and other severe immediate hypersensitivity reactions

Anaphylaxis and other severe immediate hypersensitivity reactions:

Note: IM administration in the anterolateral aspect of the middle third of the thigh is preferred; early administration (including before hospital arrival) is essential to prevent progression to life-threatening manifestations (Ref).

IM: 0.3 or 0.5 mg (use 0.5 mg in patients >50 kg unless patient is rapidly deteriorating, then may use 0.3 mg via autoinjector) using the 1 mg/mL solution; may repeat every ~5 to 15 minutes (or sooner if clinically indicated) if patient does not adequately respond. Most patients respond to the first or second dose; if inadequate response, additional measures should be instituted (eg, IV fluids and continuous IV epinephrine infusion) (Ref).

IV, intraosseous (alternative routes): Note: In general, reserve IV administration for patients who are unresponsive (eg, profoundly hypotensive) after several epinephrine IM injections. Only use intraosseous when IV access is not readily available; dosing is the same as IV route (Ref).

Continuous infusion (off label): IV: Initial: 0.1 to 0.2 mcg/kg/minute (or 8 to 16 mcg/minute for an 80 kg patient) administered with fluid resuscitation; starting dose is dependent on severity of anaphylaxis; titrate every 2 to 3 minutes by 0.05 mcg/kg/minute (or 4 mcg/minute) to response; usual dosing range: 0.01 to 0.2 mcg/kg/minute (or ~1 to 16 mcg/minute for an 80 kg patient) (Ref).

Slow IV bolus (off label): Note: Only consider in impending cardiopulmonary arrest when continuous infusion epinephrine is not immediately available; IV bolus administration may be associated with cardiac arrhythmias and cardiac ischemia (Ref).

Initial: 0.05 to 0.1 mg using the 0.1 mg/mL solution (further diluted in 10 mL of NS) administered over 1 to 10 minutes; may repeat once after 3 minutes if patient remains unresponsive to initial dose. If inadequate response, additional measures should be instituted (eg, IV fluids and continuous IV epinephrine infusion) (Ref). If patient develops cardiopulmonary arrest, use higher IV/intraosseous bolus doses (ie, 1 mg [using the 0.1 mg/mL solution] every 3 to 5 minutes) administered rapidly (see "Sudden Cardiac Arrest due to Asystole, Pulseless Electrical Activity, Ventricular Fibrillation, or Pulseless Ventricular Tachycardia [off-label use]") (Ref).

Self-treatment using auto-injector for severe allergic reactions (eg, insect stings, food):

Note: For outpatient use, prescribe at least 2 doses for patients who have a prior anaphylactic reaction and for those at risk for severe anaphylaxis (Ref).

IM (preferred route), SUBQ: 0.3 or 0.5 mg (if available, 0.5 mg dose may be used or prescribed for patients with more severe symptoms or who weigh >60 kg); may repeat every ~5 to 15 minutes (or sooner if clinically indicated) if patient does not adequately respond to initial dose; more than 2 sequential doses should only be administered under direct medical supervision; IM administration is preferred to SUBQ due to more rapid absorption and higher peak concentrations, especially when administered in the thigh (Ref).

Asthma, acute severe

Asthma, acute severe (off-label use):

Note: May use in patients who are unable to use inhaled beta-agonists. Although rare and without formal supportive data, may consider in patients who are refractory to standard therapy and are in impending respiratory arrest (Ref).

IM (preferred route), SUBQ: 0.3 to 0.5 mg using the 1 mg/mL concentration; if severe symptoms persist after initial dose, may repeat every 20 minutes for a total of 3 doses (Ref). Note: IM administration is preferred to SUBQ due to more rapid absorption and higher peak concentrations when administered in the thigh (Ref).

Bradycardia or atrioventricular block, symptomatic

Bradycardia or atrioventricular block, symptomatic (unresponsive to atropine) (off-label use):

Continuous infusion: IV: Initial: 2 to 10 mcg/minute (or 0.025 to 0.125 mcg/kg/minute for an 80 kg patient); usual dosage range: 8 to 40 mcg/minute (or 0.1 to 0.5 mcg/kg/minute for an 80 kg patient); titrate to desired effect (Ref).

Hypotension or shock

Hypotension or shock:

Cardiogenic shock (alternative agent) (off-label use):

Note: Typically, not the preferred initial agent in cardiogenic shock; consider other options. Optimal goal of therapy is not well established, but typically titrate to maintain end-organ perfusion (Ref). Institutional protocols may vary with weight-based or non-weight-based dose regimens.

Continuous infusion:

Weight-based dosing:

IV: Usual dosage range: 0.01 to 0.5 mcg/kg/minute; titrate based on clinical end point (eg, BP, end-organ perfusion) (Ref).

Non-weight-based dosing:

IV: Usual dosage range: 1 to 40 mcg/minute; titrate based on clinical end point (eg, BP, end-organ perfusion) (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources) (Ref).

Post–cardiac arrest shock (off-label use):

Note: Optimal goal of therapy is not well established, but typically titrate to mean arterial blood pressure (MAP) >65 mm Hg and preferably 80 to 100 mm Hg to optimize cerebral and end-organ perfusion (Ref). Institutional protocols may vary with weight-based or non-weight-based dose regimens.

Continuous infusion:

Weight-based dosing:

IV: Usual dosage range: 0.01 to 1 mcg/kg/minute; titrate based on clinical end points (eg, MAP, end-organ perfusion); maximum dose for refractory shock: 2 mcg/kg/minute (Ref).

Non-weight-based dosing:

IV: Usual dosage range: 1 to 80 mcg/minute; titrate based on clinical end points (eg, MAP, end-organ perfusion); maximum dose for refractory shock: 160 mcg/minute (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources) (Ref).

Septic shock and other vasodilatory shock states (adjunctive agent):

Note: Considered as adjunctive use when goal MAP not achieved with initial vasopressor or need for inotropic therapy. In general, maintain goal MAP (eg, ~65 mm Hg); consider use if patient is in shock during or after fluid resuscitation (Ref). Institutional protocols may vary with weight-based or non-weight-based dose regimens.

Continuous infusion:

Weight-based dosing:

IV: Initial: 0.01 to 0.2 mcg/kg/minute; titrate to goal MAP or end-organ perfusion; usual dose range: 0.01 to 0.5 mcg/kg/minute; maximum dose range for refractory shock: 0.5 to 2 mcg/kg/minute (Ref).

Non-weight-based dosing:

IV: Initial: 1 to 15 mcg/minute; titrate to goal MAP or end-organ perfusion; usual dose range: 1 to 40 mcg/minute; maximum dose range for refractory shock: 40 to 160 mcg/minute (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources) (Ref).

Inotropic support

Inotropic support (off-label use):

Note: Inotropic actions predominate at lower doses and vasoconstrictive actions predominate at higher doses (Ref). Institutional protocols may vary with weight-based or non-weight-based dose regimens.

Continuous infusion:

Weight-based dosing:

IV: Usual dosage range: 0.01 to 0.5 mcg/kg/minute; titrate based on clinical end point (eg, BP, end-organ perfusion) (Ref).

Non-weight-based dosing:

IV: Usual dosage range: 1 to 40 mcg/minute; titrate based on clinical end point (eg, BP, end-organ perfusion) (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources) (Ref).

Mydriasis during intraocular surgery

Mydriasis (induction and maintenance) during intraocular surgery (product specific):

Note: Must only use preservative-free vials without tartaric acid. Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information for formulation details (Ref). Protocols may vary with concentrations and dose.

Intraocular: Prior to use, must dilute 1 mL of a 1 mg/mL single-use solution to a concentration of 1 to 10 mcg/mL or if using for intracameral injection, 2.5 to 10 mcg/mL.

Irrigating solution (using 1 to 10 mcg/mL): Use as needed during the procedure (Ref).

Intracameral injection (using 2.5 to 10 mcg/mL): Injection volume: 0.1 mL (Ref).

Sudden cardiac arrest due to asystole, pulseless electrical activity, ventricular fibrillation, or pulseless ventricular tachycardia

Sudden cardiac arrest due to asystole, pulseless electrical activity, ventricular fibrillation, or pulseless ventricular tachycardia (off-label use):

IV, Intraosseous: 1 mg (using the 0.1 mg/mL solution) every 3 to 5 minutes until return of spontaneous circulation (Ref).

Endotracheal (alternative route): 2 to 2.5 mg every 3 to 5 minutes until IV/intraosseous access established or return of spontaneous circulation; before administration, dilute in 5 to 10 mL NS or sterile water (using the 1 mg/mL solution) and use hyperventilation or manual ventilation after administration (Ref). Note: May cause false-negative reading with exhaled CO2 detectors; use second method to confirm tube placement if CO2 is not detected (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Obesity: Adult

The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.

Class 1, 2, and 3 obesity (BMI ≥30 kg/m2):

Continuous infusion: IV: If institution uses weight-based dosing, use ideal body weight for initial weight-based dosing calculations, then titrate to hemodynamic effect and clinical response (Ref). If institution uses nonweight-based dosing for vasoactive agents, continue with this approach. During therapy, clinicians should not change dosing weight from one weight metric to another (ie, ideal body weight to/from actual body weight or weight-based dosing to/from nonweight-based dosing) (Ref). Refer to adult dosing for indication-specific doses.

Intermittent dosing: IM, SUBQ, intraosseous, endotracheal: Use nonweight-based dosing (Ref). Refer to adult dosing for indication specific doses.

Rationale for recommendations:

There is a paucity of studies evaluating the influence of obesity on epinephrine dosing or pharmacokinetics. Observational studies, including epinephrine, phenylephrine, and norepinephrine, suggest nonweight-based dosing strategies may result in lower overall cumulative dose requirements and increased drug exposure to second-line agents in some patients and may not be advantageous in time to achieving hemodynamic stability (Ref); however, it is difficult to show outcome differences between weight-based and nonweight-based dosing because of dose titration to target BP, particularly in the context of retrospective studies. Furthermore, there is substantial variability in response in critically ill patients, irrespective of weight. Due to the short onset of action and small Vd, rapid titration to clinical effect after initial dosing is possible (Ref).

In terms of IM administration, there are few pharmacokinetic studies in patients with obesity; however, the data do not demonstrate differences compared to patients without obesity (Ref). An observational, multicenter study in patients presenting with allergic reactions to the emergency room did not find differences in the need for repeat IM dosing between patients with obesity and those without obesity (Ref). Some experts recommend use of a longer 1.5-inch needle to penetrate the subcutaneous fat to maximize effectiveness in patients with obesity, although use of a fixed 0.3 mg dose via autoinjector is recommended in a rapidly deteriorating patient (Ref).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Epinephrine (adrenaline) (systemic): Pediatric drug information")

Dosage guidance:

Safety: Epinephrine dosage form concentrations are no longer labeled as ratio expressions (eg, 1:1,000); however, a ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (Ref).

Asystole or pulseless arrest

Asystole or pulseless arrest (Ref):

Infants, Children, and Adolescents:

IV, Intraosseous (preferred routes of administration): 0.01 mg/kg (0.1 mL/kg of 0.1 mg/mL solution) immediately after initiating CPR (within 5 minutes of starting chest compressions), maximum dose: 1 mg/dose; repeat every 3 to 5 minutes until return of spontaneous circulation.

Endotracheal: 0.1 mg/kg (0.1 mL/kg of 1 mg/mL solution) immediately after initiating CPR (within 5 minutes of starting chest compressions), maximum dose: 2.5 mg/dose; repeat every 3 to 5 minutes until return of spontaneous circulation or IV/intraosseous access established. Note: Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient beta 2-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). IV or intraosseous are the preferred methods of administration.

Bradycardia

Bradycardia (Ref):

Infants, Children, and Adolescents:

IV, Intraosseous: 0.01 mg/kg (0.1 mL/kg of 0.1 mg/mL solution) (maximum dose: 1 mg/dose or 10 mL/dose); may repeat every 3 to 5 minutes as needed.

Endotracheal: 0.1 mg/kg (0.1 mL/kg of 1 mg/mL solution) (maximum dose: 2.5 mg/dose); doses as high as 0.2 mg/kg may be effective; may repeat every 3 to 5 minutes as needed until IV/intraosseous access established. Note: Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient beta 2-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). IV or intraosseous are the preferred methods of administration.

Cardiac output increase or maintenance/post-resuscitation stabilization

Cardiac output increase or maintenance/post-resuscitation stabilization: Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: 0.05 to 1 mcg/kg/minute; doses <0.3 mcg/kg/minute generally produce beta-adrenergic effects and higher doses (>0.3 mcg/kg/minute) generally produce alpha-adrenergic vasoconstriction; titrate dosage to desired effect (Ref).

Hypersensitivity reaction/Anaphylaxis

Hypersensitivity reaction/Anaphylaxis: Note: The preferred route of administration is IM administration in the anterolateral aspect of the middle third of the thigh; SUBQ administration results in slower absorption and is less reliable (Ref).

Infants, Children, and Adolescents:

General dosing or health care settings: IM: 0.01 mg/kg/dose (0.01 mL/kg/dose of 1 mg/mL solution) not to exceed: Prepubertal child: 0.3 mg/dose; adolescent: 0.5 mg/dose; administered every 5 to 15 minutes; usual practice is to administer up to 3 doses, but more doses may be needed in some cases (Ref).

Self-/caregiver-administration following severe allergic reactions (eg, insect stings, food): Autoinjector dose: Note: If anaphylactic symptoms persist after first dose, may repeat dose in 5 to 15 minutes (Ref).

Manufacturer's labeling (eg, Adrenaclick, Auvi-Q, EpiPen Jr, EpiPen): IM, SUBQ:

7.5 to <15 kg: 0.1 mg; if anaphylactic symptoms persist, dose may be repeated based on severity and response to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.

15 to <30 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated based on severity and response to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.

≥30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated based on severity and response to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.

Alternate dosing: AAP Recommendations (Ref): Limited data available:

7.5 to <25 kg: 0.15 mg.

≥25 kg: 0.3 mg.

Refractory cases (unresponsive to IM doses): Continuous IV infusion: Prepared 1 mcg/mL solution: Initial: 0.1 mcg/kg/minute; titrate dose to response. Usual range: 0.1 to 1 mcg/kg/minute; maximum dose: 10 mcg/minute (Ref). Note: Suggested concentration of initial solution is more dilute than those typically utilized in other clinical conditions; evaluate infusion concentration with continued therapy and patient fluid status.

Hypotension/shock, fluid-resistant

Hypotension/shock, fluid-resistant: Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: 0.1 to 1 mcg/kg/minute; rates >0.3 mcg/kg/minute associated with vasopressor activity (Ref).

Mydriasis during intraocular surgery, induction, and maintenance

Mydriasis during intraocular surgery, induction, and maintenance (product specific):

Note: Not all formulations of epinephrine injection are suitable for intraocular use; consult product labeling prior to use.

Infants, Children, and Adolescents: Intraocular: Must dilute 1 mL of a 1 mg/mL preservative-/sulfite-free, single-use solution to a concentration of 1 mcg/mL to 10 mcg/mL prior to intraocular use: May use as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye) with a bolus dose of 0.1 mL of a 2.5 mcg/mL to 10 mcg/mL dilution.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined:

Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiomyopathy (stress), cerebrovascular accident, chest pain, hypertension, increased cardiac work, ischemic heart disease, limb ischemia, localized blanching, myocardial infarction, palpitations, peripheral vasoconstriction, supraventricular tachycardia, tachyarrhythmia, tachycardia, vasoconstriction, ventricular arrhythmia, ventricular ectopy, ventricular fibrillation

Central nervous system: Anxiety, apprehension, cerebral hemorrhage, disorientation, dizziness, drowsiness, exacerbation of Parkinson disease, headache, memory impairment, panic, paresthesia, psychomotor agitation, restlessness, tingling sensation

Dermatologic: Diaphoresis, gangrene of skin or other tissue (at injection site), pallor, piloerection

Endocrine & metabolic: Hyperglycemia, hypoglycemia, hypokalemia, insulin resistance, lactic acidosis

Gastrointestinal: Nausea, vomiting

Local: Tissue necrosis at injection site

Neuromuscular & skeletal: Asthenia, tremor

Renal: Renal insufficiency

Respiratory: Dyspnea, pulmonary edema, rales

Contraindications

There are no absolute contraindications to the use of injectable epinephrine (including Adrenaclick, Auvi-Q, EpiPen, EpiPen Jr, Symjepi, Allerject [Canadian product], and Twinject [Canadian product]) in a life-threatening situation. Some products include the following contraindications: Hypersensitivity to sympathomimetic amines; general anesthesia with halogenated hydrocarbons (eg, halothane) or cyclopropane; narrow angle glaucoma; nonanaphylactic shock; in combination with local anesthesia of certain areas such as fingers, toes, and ears; use in situations where vasopressors may be contraindicated (eg, thyrotoxicosis, diabetes, in obstetrics when maternal blood pressure is in excess of 130/80 mm Hg and in hypertension and other cardiovascular disorders).

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Injectable solution (Adrenalin, Epinephrine injection, USP): There are no contraindications listed in the manufacturer's labeling.

Warnings/Precautions

Concerns related to adverse effects:

• Cardiac effects: May precipitate or aggravate angina pectoris or induce cardiac arrhythmias; use with caution especially in patients with cardiac disease or those receiving drugs that sensitize the myocardium.

• Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.

• Pulmonary edema: Due to peripheral constriction and cardiac stimulation, pulmonary edema may occur.

• Renal effects: Due to renal blood vessel constriction, decreased urine output may occur.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with cardiovascular diseases (eg, arrhythmias, cerebrovascular disease, coronary artery disease, heart disease, hypertension).

• Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.

• Hypovolemia: Correct blood volume depletion before administering any vasopressor.

• Parkinson disease: Use with caution in patients with Parkinson disease; psychomotor agitation or temporary worsening of symptoms may occur.

• Pheochromocytoma: Use with caution in patients with pheochromocytoma.

• Thyroid disease: Use with caution in patients with thyroid disease.

Special populations:

• Older adults: Use with caution in older adults.

• Pediatric: Lacerations, bent needles, and embedded needles have been reported in young children who are uncooperative during injection for hypersensitivity reaction. To minimize risk, hold the child's leg firmly in place and limit movement prior to and during injection. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible (~3 seconds) (Brown 2016) (also see Administration: IM).

Dosage form specific issues:

• Accidental injection: Accidental injection into digits, hands, or feet may result in local reactions including injection-site pallor, coldness, and hypoesthesia or injury resulting in bruising, bleeding, discoloration, erythema, or skeletal injury. Patient should seek immediate medical attention if this occurs.

• Intraocular use: Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information prior to selecting a product. Appropriate products should have an indication for induction and maintenance of mydriasis during intraocular surgery and should not contain any sulfites or preservatives (ISMP 2017). Prior to intraocular use of an appropriate product, must dilute single-use 1 mg/mL (1 mL) solution to a concentration of 1 mcg/mL to 10 mcg/mL. Corneal endothelial damage has occurred when products containing sodium bisulfite have been used undiluted; therefore, dilution is advised prior to any intraocular use. In addition, products containing chlorobutanol must also not be used intraocularly (may be harmful to corneal endothelium).

• Sulfites: Some products may contain sulfites as preservatives. The presence of sulfites in some products should not deter administration during a serious allergic or other emergency situation even if the patient is sulfite-sensitive.

Other warnings/precautions:

• Appropriate use: Hypersensitivity reactions: Do not inject into the buttock; may not effectively treat anaphylaxis and has been associated with Clostridial infections (gas gangrene). Serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported rarely at the injection site. Cleansing skin with alcohol may reduce bacteria at the injection site, but alcohol cleansing does not kill Clostridium spores. Preferred injection site is anterolateral aspect of the thigh. Do not administer repeated injections at the same site (tissue necrosis may occur). Monitor for signs/symptoms of injection-site infection.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Kit, Injection:

Adyphren Amp: 1 mg/mL [DSC] [contains sodium metabisulfite]

Adyphren Amp II: 1 mg/mL [DSC] [contains sodium metabisulfite]

Adyphren II: 1 mg/mL [DSC] [contains sodium metabisulfite]

Epinephrine Professional: 1 mg/mL [contains edetate (edta) disodium dihydrate, sodium metabisulfite]

EPINEPHrinesnap: 1 mg/mL [contains edetate (edta) disodium dihydrate, sodium metabisulfite]

EpinephrineSnap-EMS: 1 mg/mL [contains edetate (edta) disodium dihydrate, sodium metabisulfite]

Epinephrinesnap-v: 1 mg/mL [contains sodium metabisulfite]

EPIsnap: 1 mg/mL [contains sodium metabisulfite]

Kit, Injection [preservative free]:

Adyphren: 1 mg/mL [DSC] [contains sodium metabisulfite]

Epinephrinesnap-v: 1 mg/mL [contains edetate (edta) disodium dihydrate, sodium metabisulfite]

Solution, Injection:

Adrenalin: 30 mg/30 mL (30 mL) [contains chlorobutanol (chlorobutol), disodium edta, sodium metabisulfite]

Generic: 1 mg/mL (10 mL); 10 mg/10 mL (10 mL); 30 mg/30 mL (30 mL)

Solution, Injection [preservative free]:

Adrenalin: 1 mg/mL (1 mL) [contains edetate (edta) disodium dihydrate, sodium metabisulfite]

Generic: 1 mg/mL (1 mL)

Solution Auto-injector, Injection:

Auvi-Q: 0.1 mg/0.1 mL (2 ea); 0.15 mg/0.15 mL (2 ea); 0.3 mg/0.3 mL (2 ea) [contains sodium bisulfite]

EpiPen 2-Pak: 0.3 mg/0.3 mL (1 ea, 2 ea) [contains sodium metabisulfite]

EpiPen Jr 2-Pak: 0.15 mg/0.3 mL (2 ea) [contains sodium metabisulfite]

Generic: 0.15 mg/0.3 mL (1 ea, 2 ea); 0.15 mg/0.15 mL (1 ea, 2 ea); 0.3 mg/0.3 mL (1 ea, 2 ea)

Solution Auto-injector, Injection [preservative free]:

Generic: 0.15 mg/0.3 mL (1 ea, 2 ea)

Solution Prefilled Syringe, Injection [preservative free]:

Symjepi: 0.15 mg/0.3 mL (1 ea [DSC], 2 ea [DSC]); 0.3 mg/0.3 mL (1 ea [DSC], 2 ea [DSC]) [latex free; contains sodium metabisulfite]

Symjepi: 0.15 mg/0.3 mL (1 ea [DSC]); 0.3 mg/0.3 mL (2 ea [DSC]) [contains sodium metabisulfite]

Generic: 1 mg/10 mL (10 mL)

Solution Prefilled Syringe, Intravenous [preservative free]:

Generic: 1 mg/10 mL (10 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Kit (EPINEPHrinesnap Injection)

1 mg/mL (per each): $148.80

Kit (EpinephrineSnap-EMS Injection)

1 mg/mL (per each): $104.40

Kit (Epinephrinesnap-v Injection)

1 mg/mL (per each): $109.20

Kit (EPIsnap Injection)

1 mg/mL (per each): $156.00

Solution (Adrenalin Injection)

1 mg/mL (per mL): $17.95

30 mg/30 mL (per mL): $10.02

Solution (EPINEPHrine (Anaphylaxis) Injection)

1 mg/mL (per mL): $17.95

30 mg/30 mL (per mL): $9.00

Solution (EPINEPHrine Injection)

1 mg/mL (per mL): $10.80

Solution (EPINEPHrine PF Injection)

1 mg/mL (per mL): $17.50

Solution Auto-injector (Auvi-Q Injection)

0.1MG/0.1ML (per each): $373.15

0.15 mg/0.15 mL (per each): $373.15

0.3 mg/0.3 mL (per each): $373.15

Solution Auto-injector (EPINEPHrine Injection)

0.15 mg/0.15 mL (per each): $247.01

0.15 mg/0.3 mL (per each): $187.50 - $346.91

0.3 mg/0.3 mL (per each): $187.50 - $346.91

Solution Auto-injector (EpiPen 2-Pak Injection)

0.3 mg/0.3 mL (per each): $365.17

Solution Auto-injector (EpiPen Jr 2-Pak Injection)

0.15 mg/0.3 mL (per each): $365.17

Solution Prefilled Syringe (EPINEPHrine Injection)

1 mg/10 mL (per mL): $1.18

Solution Prefilled Syringe (EPINEPHrine Intravenous)

1 mg/10 mL (per mL): $1.01 - $1.50

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection:

Adrenalin: 1 mg/mL (1 mL, 30 mL) [contains chlorobutanol (chlorobutol), sodium metabisulfite]

Generic: 1 mg/10 mL (10 mL); 1 mg/mL (1 mL, 10 mL)

Solution Auto-injector, Intramuscular:

Allerject: 0.15 mg/0.15 mL (1 ea); 0.3 mg/0.3 mL (1 ea) [contains sodium metabisulfite]

Anapen: 0.3 mg/0.3 mL (0.3 mL) [contains sodium metabisulfite]

Anapen Junior: 0.15 mg/0.3 mL (0.3 mL) [contains sodium metabisulfite]

Emerade: 0.5 mg/0.5 mL (1 ea) [contains edetate (edta) disodium, sodium metabisulfite]

EpiPen: 0.3 mg/0.3 mL (2 mL) [contains sodium metabisulfite]

EpiPen Jr: 0.15 mg/0.3 mL (2 mL) [contains sodium metabisulfite]

Administration: Adult

Epinephrine solutions for injection can be administered IM, intraosseous, endotracheally, IV, or SUBQ. Note: Adrenaclick, Allerject [Canadian product], Auvi-Q, EpiPen, EpiPen Jr, and Symjepi contain a single, fixed-dose of epinephrine and may only be administered IM (preferred) or SUBQ. Twinject Auto-Injectors [Canadian product] contain two doses; the first fixed-dose is available for auto-injection; the second dose is available for manual injection following partial disassembly of device.

IV : IV infusions require an infusion pump. When administering as a continuous infusion, central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line is not available, may administer for a short duration (<72 hours) through a peripheral IV catheter placed in a large vein, at a proximal site (eg, in or proximal to antecubital fossa). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (Ref). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Administration through midline catheters may also be an option (Ref).

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do NOT flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate phentolamine (or alternative antidote) (Ref).

Phentolamine: SUBQ: Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose intravenously through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (Ref).

For accidental digital epinephrine injection, inject phentolamine 0.5 to 4.5 mg (diluted in 5 mL NS) divided into multiple SUBQ injections along the area of accidental injury as soon as possible after the injury (Ref).

Alternatives to phentolamine:

Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover the affected areas; may repeat every 8 hours as necessary (Ref).

Terbutaline:

Large extravasations: SUBQ: Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS; may repeat dose after 15 minutes (Ref).

Small extravasations: SUBQ: Infiltrate affected extravasation area with 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (Ref).

SUBQ: SUBQ administration results in slower absorption and lower peak concentrations (Ref). IM administration is preferred (Ref).

IM: IM administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (Ref). Administer through clothing if necessary. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible. With nearly every device, the full dose is delivered within 3 seconds. For EpiPen, holding the device against the leg followed by removing the cap and then compressing has been described for easier administration. Never reinsert needles (Ref). Do not administer repeated injections at the same site. Do not inject into the buttocks or into digits, hands, or feet. Adrenaclick, Adrenalin, Allerject [Canadian product], Auvi-Q, EpiPen, EpiPen Jr, Symjepi, and Twinject [Canadian product] should only be injected into the anterolateral aspect of the thigh.

Obesity: For adults with obesity experiencing anaphylaxis, administer recommended dose using a 1.5-inch needle or if patient is rapidly deteriorating, use a fixed-dose autoinjector, if available (Ref). In overweight or obese children, because skin surface to muscle depth is greater in the upper half of the thigh, administration into the lower half of the thigh may be preferred. In very obese children, injection into the calf will provide an even greater chance of intramuscular administration (Ref).

Intraocular (product specific): May administer diluted solution (concentration: 1 to 10 mcg/mL) as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye). Note: Must only use preservative free vials without tartaric acid. Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information. Appropriate products should have mydriasis during intraocular surgery as an approved indication (Ref).

Endotracheal (cardiac arrest): Dilute in NS or sterile water (using the 1 mg/mL epinephrine solution). Absorption may be greater with sterile water (Ref). Stop compressions, spray drug quickly down tube. Follow immediately with several quick insufflations and continue chest compressions. May cause false-negative reading with exhaled CO2 detectors; use second method to confirm tube placement if CO2 is not detected (Ref).

Administration: Pediatric

Note: As of May 1, 2016, ratio expressions of epinephrine concentrations are prohibited on drug labels. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, the ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (Ref).

Endotracheal:

Neonates: Use 0.1 mg/mL solution.

Infants, Children, and Adolescents: Use 1 mg/mL solution; administer and flush with a minimum of 5 mL NS, followed by 5 manual ventilations.

Intraocular: Administer as a diluted solution (concentration: 1 to 10 mcg/mL) as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye). Note: Not all formulations of epinephrine injection are suitable for intraocular use; consult the product labeling prior to use. Appropriate products should have mydriasis during intraocular surgery as an approved indication and should not contain any sulfites or preservatives (Ref).

Parenteral:

Direct IV or intraosseous administration: If using 0.1 mg/mL concentration, no dilution is necessary; the 1 mg/mL concentration must be further diluted.

Continuous IV infusion: Administer as a continuous infusion via an infusion pump. Must be diluted prior to administration. Central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line not available, may administer for a short duration through a peripheral IV catheter placed in a large vein or via intraosseous access using a more dilute solution or with a second carrier fluid (Ref); frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (Ref). Note: Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Avoid use of ankle veins (due to potential for gangrene), leg veins in those suffering from occlusive vascular diseases (eg, diabetic endarteritis, Buerger disease, arteriosclerosis, atherosclerosis).

Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL)

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative antidote) (see Management of Drug Extravasations for more details). Apply dry warm compresses (Ref).

IM (eg, Auvi-Q, EpiPen, EpiPen Jr): Intramuscularly into anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (Ref). Administer through clothing if necessary. Before administering to a child, immobilize leg to prevent laceration or other injury and consider restraining children who are likely to move during administration. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible. With nearly every device, the full dose is delivered within 3 seconds. For EpiPen, holding the device against the leg followed by removing the cap and then compressing has been described for easier administration. Never reinsert needles (Ref). Do not administer repeated injections at the same site. Do not inject into the buttocks or into digits, hands, or feet. Some products are single-use products and a new device should be used for each dose; consult product specific labeling. Note: In overweight or obese children, because skin surface to muscle depth is greater in the upper half of the thigh, administration into the lower half of the thigh may be preferred. In very obese children, injection into the calf will provide an even greater chance of intramuscular administration (Ref).

SUBQ: Use only 1 mg/mL solution. Although not preferred, if used for treatment of anaphylaxis, administer into the anterolateral aspect of the middle third of the thigh (Ref).

Usual Infusion Concentrations: Adult

IV infusion: 1 mg in 250 mL (concentration: 4 mcg/mL) or 4 mg in 250 mL (concentration: 16 mcg/mL) of D5W or NS; 1 mg in 1,000 mL (concentration: 1 mcg/mL) in D5W, D5NS, or NS.

Usual Infusion Concentrations: Pediatric

IV infusion: 16 mcg/mL, 20 mcg/mL, 32 mcg/mL, 40 mcg/mL, or 64 mcg/mL.

Use: Labeled Indications

Anaphylaxis and other severe immediate hypersensitivity reactions: Treatment of type I allergic reactions, including anaphylactic reactions.

Hypotension or shock: Treatment of hypotension associated with septic shock in adults (to increase mean arterial BP).

Mydriasis during intraocular surgery (product specific): Induction and maintenance of mydriasis during intraocular surgery. Note: Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information.

Use: Off-Label: Adult

Asthma, acute severe; Bradycardia or atrioventricular block, symptomatic (unresponsive to atropine); Cardiogenic shock; Inotropic support; Post–cardiac arrest shock; Sudden cardiac arrest due to asystole, pulseless electrical activity, ventricular fibrillation, or pulseless ventricular tachycardia

Medication Safety Issues
Sound-alike/look-alike issues:

Adrenalin may be confused with Akovaz

EPINEPHrine may be confused with ePHEDrine

Epifrin may be confused with ephedrine, EpiPen

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.

Administration issues:

Medication errors have occurred due to confusion with epinephrine products expressed as ratio strengths (eg, 1:1000 vs 1:10,000).

Epinephrine 1:1000 = 1 mg/mL and is most commonly used IM

Epinephrine 1:10,000 = 0.1 mg/mL and is used IV

Medication errors have occurred when topical epinephrine 1 mg/mL (1:1000) has been inadvertently injected. Vials of injectable and topical epinephrine look very similar. Epinephrine should always be appropriately labeled with the intended administration.

EpiPen 0.3 mg and EpiPen Jr 0.15 mg auto-injectors, and authorized generic versions, may potentially have delayed injection or be prevented from properly injecting due to device failure from spontaneous activation caused by using sideways force to remove the blue safety release, device failure from inadvertent or spontaneous activation due to a raised blue safety release, difficulty removing the device from the carrier tube, and user errors. Health care providers, patients, and caregivers should periodically review the EpiPen user instructions and practice using the EpiPen trainer to ensure proper understanding and utilization of the EpiPen auto-injector. Patients and caregivers should inspect their epinephrine autoinjector prior to needing it to ensure the blue safety release is not raised and that the device can be easily removed from the carrier tube (FDA 2020).

International issues:

EpiPen [US, Canada, and multiple international markets] may be confused with Epigen brand name for glycyrrhizinic acid [Argentina, Mexico, Russia] and Epopen brand name for epoetin alfa [Spain] and Epigent brand name for gentamicin [multiple international markets]

Metabolism/Transport Effects

Substrate of COMT

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. Risk C: Monitor therapy

Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Azosemide: May diminish the therapeutic effect of EPINEPHrine (Systemic). Risk C: Monitor therapy

Benperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic). Risk C: Monitor therapy

Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Risk D: Consider therapy modification

Beta-Blockers (Beta1 Selective): May diminish the therapeutic effect of EPINEPHrine (Systemic). Risk C: Monitor therapy

Beta-Blockers (Nonselective): May enhance the hypertensive effect of EPINEPHrine (Systemic). Risk C: Monitor therapy

Beta-Blockers (with Alpha-Blocking Properties): May diminish the therapeutic effect of EPINEPHrine (Systemic). Risk C: Monitor therapy

Blonanserin: May diminish the therapeutic effect of EPINEPHrine (Systemic). Risk X: Avoid combination

Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting). Risk C: Monitor therapy

Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days. Risk D: Consider therapy modification

Bromperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic). Risk X: Avoid combination

Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider therapy modification

COMT Inhibitors: May increase the serum concentration of COMT Substrates. Risk C: Monitor therapy

Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Risk C: Monitor therapy

Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Risk X: Avoid combination

Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy

Haloperidol: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: Consider alternatives to this combination and monitor for reduced epinephrine efficacy, and possible paradoxical effects (ie, hypotension), when combined. Use of alternative vasopressor agents (eg, phenylephrine, metaraminol, norepinephrine) is preferred. Risk D: Consider therapy modification

Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated. Risk D: Consider therapy modification

Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic). Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias. Risk D: Consider therapy modification

Isoproterenol: May enhance the therapeutic effect of EPINEPHrine (Systemic). Risk X: Avoid combination

Kratom: May enhance the adverse/toxic effect of Sympathomimetics. Risk X: Avoid combination

Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine. Risk C: Monitor therapy

Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid. Risk D: Consider therapy modification

Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Risk X: Avoid combination

Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of EPINEPHrine (Systemic). Risk C: Monitor therapy

Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy

Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: Avoid epinephrine and consider norepinephrine or phenylephrine when treating hypotension due to promethazine overdose. Consider alternative vasocontrictors in patients treated with promethazine. This combination may be indicated in anaphylaxis treatment. Risk D: Consider therapy modification

Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache). Risk D: Consider therapy modification

Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Risk C: Monitor therapy

Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy

Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist. Risk D: Consider therapy modification

Vasopressin: Alpha-/Beta-Agonists (Direct-Acting) may enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced. Risk C: Monitor therapy

Pregnancy Considerations

Epinephrine crosses the placenta (Sandler 1964).

Epinephrine is recommended for the treatment of anaphylaxis in pregnant women. Specific dosing is not available; use with caution and monitor hemodynamic response (Hepner 2013). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (AHA [Jeejeebhoy 2015]).

Breastfeeding Considerations

It is not known if epinephrine is present in breast milk.

Epinephrine is generally considered compatible in breastfeeding and is recommended for the treatment of anaphylaxis in breastfeeding women (WHO 2002).

Monitoring Parameters

Heart rate, blood pressure (invasive blood pressure monitoring recommended while receiving continuous infusion); monitor site of infusion for blanching/extravasation; continuous cardiac monitoring required during continuous infusion. If using to treat hypotension, assess intravascular volume prior to and during therapy; support as needed; monitor for cardiac arrhythmias, hyperlactatemia, and hyperglycemia.

Consult individual institutional policies and procedures.

Mechanism of Action

Stimulates alpha-, beta1-, and beta2-adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation (increasing myocardial oxygen consumption), and dilation of skeletal muscle vasculature; small doses can cause vasodilation via beta2-vascular receptors; large doses may produce constriction of skeletal and vascular smooth muscle

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Bronchodilation: SUBQ: ~5 to 10 minutes

Absorption: Orally ingested doses are rapidly metabolized in GI tract and liver; pharmacologically active concentrations are not achieved

Distribution: Does not cross blood-brain barrier

Metabolism: Taken up into the adrenergic neuron and metabolized by monoamine oxidase and catechol-o-methyltransferase; circulating drug hepatically metabolized

Half-life elimination: IV: <5 minutes

Excretion: Urine (as inactive metabolites, metanephrine, and sulfate and hydroxy derivatives of mandelic acid, small amounts as unchanged drug)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Adrenaline | Epipen | Jext;
  • (AR) Argentina: Adrenalina Bioquim;
  • (AT) Austria: Adrenalin aguettant | Emerade | Epipen | L-adrenalin;
  • (AU) Australia: Adrenaline | Adrenaline aguettant | Adrenaline jr mylan | Adrenaline mylan | Emerade | Epipen;
  • (BE) Belgium: Adrenaline (tartrate) aguettant | Adrenaline Parke-Davis | Anahelp | Epipen;
  • (BG) Bulgaria: Adrenalin;
  • (CH) Switzerland: Adrenalin labatec | Emerade | Epipen;
  • (CL) Chile: Epipen;
  • (CO) Colombia: Epinefrina | Penepin jr;
  • (CZ) Czech Republic: Adrenalin | Emerade | Epipen;
  • (DE) Germany: ADRENALIN Carino | Adrenalin ethypharm | Adrenalin Infectopharm | Anapen | Emerade | Epipen | Fastjekt | Jext | Min-I-Jet Adrenalin;
  • (DK) Denmark: Epipen;
  • (DO) Dominican Republic: Adrenalina;
  • (EE) Estonia: Adrenalini hcl | Epipen;
  • (EG) Egypt: Adrenaline;
  • (ES) Spain: Adreject | Adrenalina level | Altellus | Anapen | Emerade;
  • (FI) Finland: Adrenalin aguettant | Adrenalin stragen | Emerade | Epipen;
  • (FR) France: Adrenaline aguettant | Adrenaline b.braun | Adrenaline cooper | Adrenaline PCH | Anahelp | Anakit | Anapen | Emerade | Epipen;
  • (GB) United Kingdom: Adrenaline | Emerade | Epipen | Ims adrenaline | Jext;
  • (GR) Greece: Adrenalina wzf | Anapen | Emerade | Epipen | Fastjekt | Jext;
  • (HK) Hong Kong: Epinephrine minijet;
  • (HR) Croatia: EpiPen Jr;
  • (ID) Indonesia: Adrenaline | Adrenalini bitartras;
  • (IE) Ireland: Adrenaline | Anapen | Epipen;
  • (IL) Israel: Epipen;
  • (IT) Italy: Adrenalina | Adrenalina Aguettant | Chenpen | Fastjekt | Fastjekt junior;
  • (JP) Japan: Epipen | Epiquick;
  • (KE) Kenya: Adrenaline aguettant;
  • (KR) Korea, Republic of: Jext;
  • (KW) Kuwait: Adrenaline | Adrenaline aguettant | Epipen | EpiPen Jr;
  • (LT) Lithuania: Adrenalin | Adrenalina wzf | Fastjekt;
  • (LU) Luxembourg: Adrenaline (tartrate) aguettant | Fastjekt | Jext;
  • (LV) Latvia: Adrenalin | Adrenalini | Adrenalini hydrotartras;
  • (MY) Malaysia: Adrenaline;
  • (NL) Netherlands: Adrenaline | Emerade | Epipen | Jext;
  • (NO) Norway: Adrenalin aguettant | Adrenalin stragen | Adrenaline aurum | Emerade | Epipen;
  • (NZ) New Zealand: Adrenaline aguettant | Epipen;
  • (PK) Pakistan: Adrenaline;
  • (PL) Poland: Adrenalina Aguettant | Adrenalina wzf | Adrenalinum | Fastjekt;
  • (PR) Puerto Rico: Adrenalin chloride | Epinephrine | Epipen | Epipen 2-Pak | Epipen jr 2-pak | Symjepi;
  • (PT) Portugal: Adrenalina | Emerade | Epipen | Spinefe;
  • (PY) Paraguay: Adrenalina lasca;
  • (QA) Qatar: Emerade | EpiPen | Penepin;
  • (RO) Romania: Anapen | Epipen;
  • (RU) Russian Federation: Adrenalin | Epigect;
  • (SA) Saudi Arabia: Adrenaline | Epipen | Jext;
  • (SE) Sweden: Adrenalin mylan | Adrenalin stragen | Anapen | Emerade | Epipen | EpiPen Jr | Jext;
  • (SG) Singapore: Adrenaline;
  • (SI) Slovenia: Adrenalin aguettant | Epipen;
  • (SK) Slovakia: Adrenalin | Epipen;
  • (TN) Tunisia: Anapen;
  • (TR) Turkey: Adrenalin | Penepin;
  • (TW) Taiwan: Bosmin | Epirenamin;
  • (UA) Ukraine: Adrenalin | Epipen | Epipen junior;
  • (UY) Uruguay: Adrenalina;
  • (VE) Venezuela, Bolivarian Republic of: Adrenalina;
  • (ZA) South Africa: Adrenaline | Adrenotone | Anaguard | Epipen
  1. “2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2005, 112(24 Suppl): 1-211.
  2. Adams C, Tucker C, Allen B, et al. Disparities in hemodynamic resuscitation of the obese critically ill septic shock patient. J Crit Care. 2017;37:219-223. doi:10.1016/j.jcrc.2016.10.004 [PubMed 27969574]
  3. Adrenaclick (epinephrine) [prescribing information]. McPherson, KS; Hospira, Inc; February 2021.
  4. Adrenalin (epinephrine) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceuticals; June 2022.
  5. Allerject (epinephrine) [Canadian prescribing information]. Richmond, VA: Kaleo, Inc; November 2019.
  6. American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed February 15, 2022.
  7. Annane D, Vignon P, Renault A, et al; CATS Study Group. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007;370(9588):676-684. doi:10.1016/S0140-6736(07)61344-0 [PubMed 17720019]
  8. Arkwright P, Wright N, Bewick D, “Anatomical and Anthropometric Determinants of Intramuscular versus Subcutaneous Administration in Children With Epinephrine Auto-injectors,” J Allergy Clin Immunol, 2013, 131(2):AB199.
  9. Auvi-Q (epinephrine) [prescribing information]. Richmond, VA: Kaleo Inc; September 2019.
  10. Aziz K, Lee CHC, Escobedo MB, et al. Part 5: Neonatal resuscitation 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Pediatrics. 2021;147(Suppl 1):e2020038505E. doi:10.1542/peds.2020-038505E [PubMed 33087555]
  11. Baker TW, Webber CM, Stolfi A, Gonzalez-Reyes E. The TEN study: time epinephrine needs to reach muscle. Ann Allergy Asthma Immunol. 2011;107(3):235-238. doi: 10.1016/j.anai.2011.06.001. [PubMed 21875542]
  12. Barach EM, Nowak RM, Lee TG, Tomlanovich MC. Epinephrine for treatment of anaphylactic shock. JAMA. 1984;251(16):2118-2122. [PubMed 6708262]
  13. Based on expert opinion.
  14. Brierley J, Carcillo JA, Choong K, et al, “Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,” Crit Care Med, 2009, 37(2):666-88. [PubMed 19325359]
  15. Brown JC, Tuuri RE, Akhter S, et al. Lacerations and embedded needles caused by epinephrine autoinjector use in children. Ann Emerg Med. 2016;67(3):307-315.e8. doi: 10.1016/j.annemergmed.2015.07.011. [PubMed 26452720]
  16. Brown SG, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J. 2004;21(2):149-154. doi:10.1136/emj.2003.009449 [PubMed 14988337]
  17. Callaway CW, Donnino MW, Fink EL, et al. Part 8: post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18)(suppl 2):S465-S482. doi:10.1161/CIR.0000000000000262 [PubMed 26472996]
  18. Campbell RL, Bellolio MF, Knutson BD, et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol Pract. 2015;3(1):76-80. doi:10.1016/j.jaip.2014.06.007 [PubMed 25577622]
  19. Campbell RL, Kelso JM. Anaphylaxis: emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 2, 2022.
  20. Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol. 2014;113(6):599-608. doi:10.1016/j.anai.2014.10.007 [PubMed 25466802]
  21. Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med. 2015;10(9):581-585. doi:10.1002/jhm.2394 [PubMed 26014852]
  22. Cheng A. Emergency treatment of anaphylaxis in infants and children. Paediatr Child Health. 2011;16(1):35-40. [PubMed 22211074]
  23. Cydulka R. Chapter 69. Acute Asthma. In: Tintinalli J, Stapczynski JS, Ma OJ, et al. Tintinalli's Emergency Medicine. 8th ed. New York, NY: McGraw-Hill; 2016.
  24. Cydulka R, Davison R, Grammer L, et al, “The Use of Epinephrine in the Treatment of Older Adult Asthmatics,” Ann Emerg Med, 1988, 17(4):322-6. [PubMed 3354935]
  25. Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med. 2017;45(6):1061-1093.doi: 10.1097/CCM.0000000000002425. [PubMed 28509730]
  26. Davis C and Wax P, “Subcutaneous Epinephrine O.D. in a Child Resulting in Dysrhythmias and Myocardial Ischemia,” Vet Hum Toxicol, 1994, 36:367.
  27. DeBehnke DJ. Endotracheal epinephrine administration. Acad Emerg Med. 1994;1(4):326-327. doi:10.1111/j.1553-2712.1994.tb02637.x [PubMed 7614276]
  28. Dellinger RP, Schorr CA, Levy MM. A users' guide to the 2016 surviving sepsis guidelines. Crit Care Med. 2017;45(3):381-385. doi:10.1097/CCM.0000000000002257 [PubMed 28099222]
  29. Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. Cloherty and Stark's Manual of Neonatal Care. 8th edition. Lippincott Williams & Wilkins; 2017.
  30. Emerade (epinephrine) [product monograph]. Laval, Quebec, Canada: Bausch Health; June 15, 2020.
  31. Epinephrine injection [prescribing information]. Freehold, NJ: BPI Labs, LLC; June 2017.
  32. Epinephrine Injection [prescribing information]. Lake Forest, IL: Hospira Inc; September 2022.
  33. Epinephrine injection (auto-injector) [prescribing information]. Lineage Therapeutics Inc.; Horsham, PA: May 2016.
  34. EpiPen/EpiPen Jr (epinephrine) [prescribing information]. St. Louis, MO: Meridian Medical Technologies LLC; February 2023.
  35. Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. Crit Care. 2021;25(1):77. doi:10.1186/s13054-021-03495-8 [PubMed 33622380]
  36. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337 [PubMed 34605781]
  37. Expert Panel Report 3, “Guidelines for the Diagnosis and Management of Asthma,” Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm
  38. Field JM, Hazinski MF, Sayre MR, et al, “Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122 (18 Suppl 3):640-56. [PubMed 20956217]
  39. Gillies M, Bellomo R, Doolan L, Buxton B. Bench-to-bedside review: inotropic drug therapy after adult cardiac surgery – a systematic literature review. Crit Care. 2005;9(3):266-279. doi:10.1186/cc3024 [PubMed 15987381]
  40. Heckmann M, Trotter A, Pohlandt F, Lindner W. Epinephrine treatment of hypotension in very low birthweight infants. Acta Paediatr. 2002;91(5):566-570. [PubMed 12113327]
  41. Hepner DL, Castells M, Mouton-Faivre C, Dewachter P. Anaphylaxis in the clinical setting of obstetric anesthesia: a literature review. Anesth Analg. 2013;117(6):1357-1367. [PubMed 24257386]
  42. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32(9):1928-1948. doi:10.1097/01.ccm.0000139761.05492.d6 [PubMed 15343024]
  43. Hurst S and McMillan M, “Innovative Solutions in Critical Care Units: Extravasation Guidelines,” Dimens Crit Care Nurs, 2004, 23(3):125-8. [PubMed 15192356]
  44. Institute for Safe Medication Practices (ISMP). Farewell to ratio expressions on single entity drug labels. Acute Care ISMP Medication Safety Alert! 2015;20(24):2-3.
  45. Institute for Safe Medication Practices (ISMP). Mydriasis indication eliminated from Adrenalin brand! Acute Care ISMP Medication Safety Alert. 2017;22(12):1-2.
  46. Institute for Safe Medication Practices (ISMP) and Vermont Oxford Network, “Standard Concentrations of Neonatal Drug Infusions,” 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf
  47. Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. Circulation. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300. [PubMed 26443610]
  48. Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics. 2010;126(5):e1400-1413. [PubMed 20956432]
  49. Kemp SF, Lockey RF, Simons FE, et al, “Epinephrine: The Drug of Choice for Anaphylaxis. A Statement of the World Allergy Organization,” Allergy, 2008, 63(8):1061-70. [PubMed 18691308]
  50. Kleinman ME, Chameides L, Schexnayder SM, et al, “Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122(18 Suppl 3):876-908. [PubMed 20956230]
  51. Kostakou E, Kaniaris E, Filiou E, et al. Acute severe asthma in adolescent and adult patients: current perspectives on assessment and management. J Clin Med. 2019;8(9):1283. doi:10.3390/jcm8091283 [PubMed 31443563]
  52. Kränke B, Schuster C, Wiednig M, Reiter H. A simple method to improve safety of epinephrine auto-injectors. Pediatr Allergy Immunol. 2012;23(4):399-400. doi: 10.1111/j.1399-3038.2012.01299.x. [PubMed 22594931]
  53. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(7):932‐987. doi:10.1016/j.jacc.2018.10.043 [PubMed 30412710]
  54. Lamontagne F, Richards-Belle A, Thomas K, et al; 65 trial investigators. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. JAMA. 2020;323(10):938-949. doi:10.1001/jama.2020.0930 [PubMed 32049269]
  55. Le Tulzo Y, Seguin P, Gacouin A, et al. Effects of epinephrine on right ventricular function in patients with severe septic shock and right ventricular failure: a preliminary descriptive study. Intensive Care Med. 1997;23(6):664-670. doi:10.1007/s001340050391 [PubMed 9255647]
  56. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 Update. Crit Care Med. 2018;46(6):997-1000. doi: 10.1097/CCM.0000000000003119 [PubMed 29767636]
  57. Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the peripheral administration of vasopressor agents. J Intensive Care Med. 2019;34(1):26-33. doi:10.1177/0885066616686035 [PubMed 28073314]
  58. Lieberman P. The 10-second rule and other myths about epinephrine and autoinjectors. Ann Allergy Asthma Immunol. 2011;107(3):189-190. doi: 10.1016/j.anai.2011.07.007. [PubMed 21875535]
  59. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384. doi:10.1016/j.anai.2015.07.019 [PubMed 26505932]
  60. Long B, Lentz S, Koyfman A, Gottlieb M. Evaluation and management of the critically ill adult asthmatic in the emergency department setting. Am J Emerg Med. 2020;S0735-6757(20)30171-30176. doi:10.1016/j.ajem.2020.03.029 [PubMed 32222313]
  61. Manaker S. Use of vasopressors and inotropes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 18, 2020.
  62. Medlej K, Kazzi AA, El Hajj Chehade A, et al. Complications from administration of vasopressors through peripheral venous catheters: an observational study. J Emerg Med. 2018;54(1):47-53. doi:10.1016/j.jemermed.2017.09.007 [PubMed 29110979]
  63. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J; CAT Study investigators. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34(12):2226-2234. doi:10.1007/s00134-008-1219-0 [PubMed 18654759]
  64. Naganobu K, Hasebe Y, Uchiyama Y, et al, “A Comparison of Distilled Water and Normal Saline as Diluents for Endobronchial Administration of Epinephrine in the Dog,” Anesth Analg, 2000, 91(2):317-21. [PubMed 10910841]
  65. National Asthma Education and Prevention Program, "Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma," Bethesda, MD, National Institutes of Health, 1997. NIH publication 97-4051.
  66. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18)(suppl 3):S729‐S767. doi:10.1161/CIRCULATIONAHA.110.970988 [PubMed 20956224]
  67. Neumar RW, Shuster M, Callaway CW, et al. Part 1: executive summary: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18)(suppl 2):S315–S367. doi: 10.1161/CIR.0000000000000252. [PubMed 26472989]
  68. Panchal AR, Berg KM, Hirsch KG, et al. 2019 American Heart Association focused update on advanced cardiovascular life support: use of advanced airways, vasopressors, and extracorporeal cardiopulmonary resuscitation during cardiac arrest: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2019;140(24):e881-e894. doi:10.1161/CIR.0000000000000732 [PubMed 31722552]
  69. Peberdy MA, Callaway CW, Neumar RW, et al; American Heart Association. Part 9: post–cardiac arrest care: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18)(suppl 3):S768-S786. doi:10.1161/CIRCULATIONAHA.110.971002 [PubMed 20956225]
  70. Pellicer A, Valverde E, Elorza MD, et al. Cardiovascular support for low birth weight infants and cerebral hemodynamics: a randomized, blinded, clinical trial. Pediatrics. 2005;115(6):1501-1512. [PubMed 15930210]
  71. Perkins GD, Ji C, Deakin CD, et al. A randomized trial of epinephrine in out-of-hospital cardiac arrest. N Engl J Med. 2018;379(8):711-721. doi:10.1056/NEJMoa1806842. [PubMed 30021076]
  72. Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” Am J Health Syst Pharm, 2011, 68(22):2176-82. [PubMed 22058104]
  73. Prasanna N, Yamane D, Haridasa N, Davison D, Sparks A, Hawkins K. Safety and efficacy of vasopressor administration through midline catheters. J Crit Care. 2021;61:1-4. doi:10.1016/j.jcrc.2020.09.024 [PubMed 33049486]
  74. Radosevich JJ, Patanwala AE, Erstad BL. Norepinephrine dosing in obese and nonobese patients with septic shock. Am J Crit Care. 2016;25(1):27-32. doi:10.4037/ajcc2016667 [PubMed 26724290]
  75. Refer to manufacturer's labeling.
  76. Reynolds PM, Maclaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617-632. DOI: 10.1002/phar.1396 [PubMed 24420913]
  77. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486-552. doi:10.1097/CCM.0000000000002255 [PubMed 28098591]
  78. Rittenberger JC, Callaway CW. Post-cardiac arrest management in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 15, 2020.
  79. Rotta AT, Wiryawan B. Respiratory emergencies in children. Respir Care. 2003;48(3):248-258. [PubMed 12667275]
  80. Rudders SA, Geyer BC, Banerji A, Phipatanakul W, Clark S, Camargo CA Jr. Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis. J Allergy Clin Immunol. 2012;130(5):1216-1218. doi:10.1016/j.jaci.2012.08.029 [PubMed 23021879]
  81. Russell JA, Walley KR, Singer J, et al, “Vasopressin Versus Norepinephrine Infusion in Patients With Septic Shock,” N Engl J Med, 2008, 358(9):877-87. [PubMed 18305265]
  82. Sandler M, Ruthren CR, Wood C. Metabolism of C14-norepinephrine and 14-epinephrine and their transmission across the human placenta. Int J Neuropharmacol. 1964;3:123-128. [PubMed 14334587]
  83. Shah R, Saltoun CA. Chapter 14: Acute severe asthma (status asthmaticus). Allergy Asthma Proc. 2012;(33)(suppl 1):47-50. doi:10.2500/aap.2012.33.3547 [PubMed 22794687]
  84. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017 [PubMed 32001253]
  85. Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. Pediatrics. 2020;145(1):e20193450. [PubMed 31871244]
  86. Sicherer SH, Simons FER; Section on Allergy and Immunology. Epinephrine for first-aid management of anaphylaxis. Pediatrics. 2017;139(3). doi: 10.1542/peds.2016-4006. [PubMed 28193791]
  87. Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011;127(3):587-593. doi:10.1016/j.jaci.2011.01.038 [PubMed 21377030]
  88. Simons FE, Ebisawa M2, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015 Oct 28;8(1):32. [PubMed 26525001]
  89. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001;108(5):871-873. doi:10.1067/mai.2001.119409 [PubMed 11692118]
  90. Smetzer J, Cohen M, eds. Mydriasis indication eliminated from Adrenalin brand. ISMP Medication Safety Alert! Acute Care Edition. 2017;22(12):1-2.
  91. Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. Pharmacotherapy. 2023;43(4):321-337. doi:10.1002/phar.2794 [PubMed 36938775]
  92. Stier PA, Bogner MP, Webster K, et al, "Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia," Am J Emerg Med, 1999, 17(1):91-4. [PubMed 9928712]
  93. Symjepi (epinephrine) injection [prescribing information]. San Diego, CA: Adamis Pharmaceuticals Corp; June 2021.
  94. Tian DH, Smyth C, Keijzers G, et al. Safety of peripheral administration of vasopressor medications: A systematic review. Emerg Med Australas. 2020;32(2):220-227. doi:10.1111/1742-6723.13406 [PubMed 31698544]
  95. Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16 Suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901 [PubMed 33081526]
  96. Trissel LA. Handbook on Injectable Drugs. 18th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2014.
  97. Twinject (epinephrine) [product monograph]. Montreal, QC: Paladin Labs Inc; December 2012.
  98. US Food and Drug Administration (FDA). FDA Drug Safety Communication. MedWatch. FDA alerts patients and health care professionals of EpiPen auto-injector errors related to device malfunctions and user administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-and-health-care-professionals-epipen-auto-injector-errors-related-device. Published March 24, 2020. Accessed March 8, 2021.
  99. Vadiei N, Daley MJ, Murthy MS, Shuman CS. Impact of norepinephrine weight-based dosing compared with non-weight-based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock. Ann Pharmacother. 2017;51(3):194-202. doi:10.1177/1060028016682030 [PubMed 27886982]
  100. Valverde E, Pellicer A, Madero R, Elorza D, Quero J, Cabañas F. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes. Pediatrics. 2006;117(6):e1213-1222. [PubMed 16717120]
  101. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18)(suppl 3):S829-S861. doi:10.1161/CIRCULATIONAHA.110.971069 [PubMed 20956228]
  102. van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525 [PubMed 28923988]
  103. Waisman Y, Klein BL, Boenning DA, et al, “Prospective Randomized Double-Blind Study Comparing L-Epinephrine and Racemic Epinephrine Aerosols in the Treatment of Laryngotracheitis (Croup),” Pediatrics, 1992, 89(2):302-6. [PubMed 1734400]
  104. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med. 2020;21(2):e52-e106. doi:10.1097/PCC.0000000000002198 [PubMed 32032273]
  105. Wenzel V, Krismer AC, Arntz HR, et al, “A Comparison of Vasopressin and Epinephrine for Out-of-Hospital Cardiopulmonary Resuscitation. European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group,” N Engl J Med, 2004, 350(2):105-13. [PubMed 14711909]
  106. Wong AF, McCulloch LM, and Sola A, “Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates,” J Pediatr, 1992, 121(6):980-3. [PubMed 1447671]
  107. World Health Organization; UNICEF. Department of Maternal, newborn, child and adolescent health. Breastfeeding and maternal medication: recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. World Health Organization. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002. Accessed August 28, 2018.
  108. Worm M, Nguyen D, Rackley R, et al. Epinephrine delivery via EpiPen Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances. Clin Transl Allergy. 2020;10:21. doi:10.1186/s13601-020-00326-x [PubMed 32528643]
  109. Zakka K, Gadi S, Koshlelashvili N, Maleque NM. Acute myocardial injury after administration of intravenous epinephrine for allergic reaction. SAGE Open Med Case Rep. 2020. doi:10.1177/2050313X20933104 [PubMed 32595973]
Topic 105602 Version 429.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟